URGN实时信号 | 通过Getagraph.com最大化利润

出售 108254 min ago

@ $19.19

发出时间: 14 Feb 2024 @ 00:02

回报率: -26.27%

上一信号: Feb 13 - 04:11

上一信号: 购买

回报率: -0.20 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases...

Stats
今日成交量	135 619
平均成交量	364 868
市值	482.83M
EPS	$0 ( 2024-03-21 )
下一个收益日期	( $-0.930 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.99
ATR14	$0.0290 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Schoenberg Mark	Sell	12 000	Ordinary Shares
2024-01-31	Kim Dong	Buy	3 333	Ordinary Shares
2022-03-25	Kim Dong	Buy	20 000	Stock Option (right to buy)
2024-02-01	Smith Jason Drew	Sell	3 328	Ordinary Shares
2024-02-01	Smith Jason Drew	Sell	1 248	Ordinary Shares

INSIDER POWER
58.83
Last 96 transactions
Buy: 1 308 776 \| Sell: 407 960

音量相关性

長: 0.26 (neutral)

短: -0.02 (neutral)

Signal:(62.511) Neutral

Urogen Pharma Ltd 相关性

10 最正相关
SVAC	0.916
GOODM	0.907
TLGT	0.891
MTSL	0.871
NSTS	0.866
TTWO	0.86
LUNG	0.851
PAIC	0.851
RMNI	0.845
RCM	0.833

10 最负相关
LWAC	-0.955
SRAC	-0.919
AMRB	-0.902
LMRKN	-0.889
NETE	-0.881
KNSA	-0.847
UTHR	-0.847
RAVN	-0.84
OFS	-0.831
TECH	-0.828

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Urogen Pharma Ltd 相关性 - 货币/商品

0.18
( neutral )

0.13
( neutral )

0.00
( neutral )

-0.39
( neutral )

-0.17
( neutral )

0.09
( neutral )

Urogen Pharma Ltd 财务报表

Annual	2023
营收:	$82.71M
毛利润:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2023
营收:	$82.71M
毛利润:	$73.35M (88.68 %)
EPS:	$-3.55

FY	2022
营收:	$64.36M
毛利润:	$56.70M (88.11 %)
EPS:	$-4.79

FY	2021
营收:	$48.04M
毛利润:	$42.89M (89.27 %)
EPS:	$-4.96

Financial Reports:

No articles found.

Urogen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.